opgn stock forecast zacks

Their forecasts range from 400 to 600. On average they expect Citius Pharmaceuticals stock price to reach 500 in the next year.

Opgen Inc Opgn Stock Price Quote News Stock Analysis

NEPH stock forecast Our latest prediction for Nephros Incs stock price was made on the Aug.

. Find the latest OpGen Inc. Interested parties can register for or listen to the call. Common Stock OPGN.

OpGen will be holding an earnings conference call on Tuesday March 29th at 430 PM Eastern. OpGen NASDAQ Updated Mar 18 2022 455 PM. Gain free stock research access to stock picks stock screeners stock reports portfolio.

OPGN Complete OpGen Inc. Buy or sell Opgen stock. An industry with a larger percentage of Zacks Rank 1s and 2s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank 4s and 5s.

The brokerage presently has a 075 price target on the medical research companys stock. In the short term 2weeks NEPHs stock price should underperform the market by -160During that period the price should oscillate between -1026 and 1118. View real-time stock prices and stock quotes for a full financial overview.

OPGN 087 001 120. Get the latest Full Company Report for OpGen from Zacks Investment Research. Zacks proprietary data indicates that OpGen Inc.

Opgen Inc Stock Market info Recommendations. OPGN stock quote history news and other vital information to help you with your stock trading and investing. Zacks Investment Researchs price objective points to a potential.

Is a microbial genetics analysis company. Their forecasts range from 300 to 400. Zacks Investment Research is releasing its prediction for OPGN based on the 1-3 month trading system that nearly triples the SP 500.

Click here - the OPGN analysis is free About Broker. Stock news by MarketWatch. Skip to main content SP 500 425952.

Read our earnings report guide before you consider the forecast information when. 18 2021 when the stock price was at 760. Wall Street Stock Market Finance report prediction for the future.

OpGen has confirmed that its next quarterly earnings report will be published on Tuesday March 29th 2022. Is currently rated as a Zacks Rank 2 and we are expecting an above average return from the OPGN shares. In the medium term 3months NEPHs stock price should.

The industry with the best average Zacks Rank would be considered the top industry 1 out of 265 which would place it in the top 1 of Zacks Ranked Industries. On average they expect OpGens share price to reach 350 in the next year. OpGen - Full Company Report.

This suggests a possible upside of 3845 from the stocks current price. View ENZs stock price price target earnings financials forecast insider trades news and SEC filings at MarketBeat. Zacks Investment Research is releasing its prediction for OPGN based on the 1-3 month trading system that nearly triples the SP 500.

Get the latest Mogo Inc MOGO detailed stock quotes stock data Real-Time ECN charts stats and more. View Mogo Inc MOGO investment stock information. OPGN Earnings Information.

This suggests a possible upside of 2268 from the stocks current price. Youll find the Opgen share forecasts stock quote and buy sell signals belowAccording to present data Opgens OPGN shares and potentially its market environment have been in bearish cycle last 12 months if exists. The 2 analysts offering 12-month price forecasts for OpGen Inc have a median target of 350 with a high estimate of 400 and a.

Or dial in at 412-317-6671 with passcode 13726634. Ad Nasdaq Morningstar and others use Zacks research but you wont see these picks there. Zacks picks shot up 36 40 even 46 in the past 30 days.

View analysts price targets for Citius Pharmaceuticals or view top-rated stocks among Wall Street analysts. View analysts price targets for OpGen or. The Company offers optical mapping services for analysis of microbial yeast and fungal genomic architecture.

Click here - the OPGN analysis is free About Price and. Zacks is the leading investment research firm focusing on stock research analysis and recommendations.

Opgen Price Target Analyst Ratings Nasdaq Opgn